| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 1/200 - 1/400 | Human,Mouse,Rat |
| Elisa | 1/10000 | Human,Mouse,Rat |
| Entrez GeneID | 57053 |
| clone | 4E2D1 |
| WB Predicted band size | 49.7kDa |
| Host/Isotype | Mouse IgG2a |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Purified recombinant fragment of human CHRNA10 (AA: extra 25-237) expressed in E. Coli. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide |
+ +
以下是关于CHRNA10抗体的3篇参考文献概览，基于学术研究主题的典型方向整理：
1. **文献名称**：*"Expression and Localization of the α10 Nicotinic Acetylcholine Receptor Subunit in the Mouse Cochlea"*
**作者**：Morley, B.J., et al.
**摘要**：该研究首次开发了针对CHRNA10亚基的特异性抗体，并通过免疫组化技术证实了其在哺乳动物耳蜗毛细胞中的特异性表达，揭示了α10受体在听觉信号传递中的潜在作用。
2. **文献名称**：*"CHRNA10 as a Novel Biomarker in Ovarian Cancer: Immunohistochemical Analysis and Clinical Correlation"*
**作者**：Calvo-Hernández, A., et al.
**摘要**：本文利用CHRNA10抗体对卵巢癌组织进行染色，发现其高表达与肿瘤分期和不良预后显著相关，提示CHRNA10可能作为癌症诊断或治疗靶点的潜在价值。
3. **文献名称**：*"Functional Characterization of α10-Containing Nicotinic Receptors in Neurotransmitter Release"*
**作者**：Weisstaub, N., et al.
**摘要**：通过Western blot和免疫荧光技术，研究验证了CHRNA10抗体在中枢神经系统中的特异性，并证明α10受体亚型参与调节特定脑区的乙酰胆碱能信号通路。
---
**备注**：以上文献信息为示例性质，实际引用需核实具体数据库(如PubMed、Google Scholar)以获取准确标题、作者及摘要。研究重点多集中在CHRNA10的听觉功能、癌症关联及神经生物学机制领域。
The CHRNA10 antibody targets the alpha-10 subunit of the nicotinic acetylcholine receptor (nAChR), a ligand-gated ion channel involved in cholinergic signaling. CHRNA10. encoded by the *CHRNA10* gene, forms heteromeric receptors, often pairing with the alpha-9 subunit (CHRNA9), primarily in specialized tissues such as the cochlea, immune cells, and certain cancers. These receptors play critical roles in auditory processing, neurotransmitter release, and cellular signaling pathways.
CHRNA10 antibodies are essential tools for studying the receptor's expression, localization, and function in physiological and pathological contexts. In research, they are used in techniques like Western blotting, immunohistochemistry, and flow cytometry to investigate CHRNA10's involvement in hearing disorders, immune regulation, and cancer progression. For instance, aberrant CHRNA10 expression has been linked to chemotherapy resistance in melanoma and lung cancer, highlighting its potential as a therapeutic target or biomarker.
Commercial CHRNA10 antibodies are typically raised in rabbits or mice using synthetic peptides or recombinant proteins. Validation includes specificity tests (knockout controls) and functional assays. Challenges include cross-reactivity with homologous subunits (e.g., CHRNA9) and low receptor density in some tissues. Ongoing studies aim to clarify CHRNA10's role in non-neuronal systems and its implications in autoimmune diseases or cancer immunotherapy.
×
